[{"orgOrder":0,"company":"MorphoSys","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"MorphoSys","amount2":2,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":2,"dosageForm":"","sponsorNew":"MorphoSys \/ Incyte","highestDevelopmentStatusID":"9","companyTruncated":"MorphoSys \/ Incyte"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"TG Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"3-Aminopyrrolidine dihydrochloride","moa":"VISTA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curis \/ Aurigene Discovery Technologies","highestDevelopmentStatusID":"9","companyTruncated":"Curis \/ Aurigene Discovery Technologies"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"United Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Omburtamab","moa":"Beta\/gamma radiation","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebroventricular","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"TG Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"SUO-CTC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Nadofaragene firadenovec","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"SUO-CTC","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"SUO-CTC \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"SUO-CTC \/ Not Applicable"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Global Coalition for Adaptive Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Global Coalition for Adaptive Research","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Therapeutics \/ Global Coalition for Adaptive Research"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Margetuximab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"MacroGenics \/ Not Applicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"HSBC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Hafnium Oxide","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Nanobiotix","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ HSBC","highestDevelopmentStatusID":"9","companyTruncated":"Nanobiotix \/ HSBC"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"National Brain Tumor Society","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ National Brain Tumor Society","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Therapeutics \/ National Brain Tumor Society"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Omburtamab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Margetuximab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"MacroGenics \/ Not Applicable"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"131I-omburtamab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Margetuximab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Zai Lab \/ Not Applicable"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Global Coalition for Adaptive Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Global Coalition for Adaptive Research","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Therapeutics \/ Global Coalition for Adaptive Research"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Karyopharm Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Diethyl dihydroxyhomospermine","moa":"Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"NovoCodex","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"ARX788","moa":"HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Ambrx Inc \/ NovoCodex","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ NovoCodex"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ono Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"ARX788","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Not Applicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Diethyl dihydroxyhomospermine","moa":"Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"AL102","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Ayala Pharmaceuticals \/ Jefferies LLC","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Jefferies LLC"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"ARX788","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Belapectin","moa":"Galectin-3","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Galectin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kartos Therapeutics","sponsor":"Illumina","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"KRT-232","moa":"MDM2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kartos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kartos Therapeutics \/ Illumina","highestDevelopmentStatusID":"9","companyTruncated":"Kartos Therapeutics \/ Illumina"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Bionical Emas","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Recombinant Asparaginase Erwinia chrysanthemi","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Jazz Pharmaceuticals \/ Bionical Emas","highestDevelopmentStatusID":"9","companyTruncated":"Jazz Pharmaceuticals \/ Bionical Emas"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bintrafusp Alfa","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Merck Group \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Merck Group \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Sun Yat-sen University","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Therapeutics \/ Sun Yat-sen University"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Financing","leadProduct":"Eftilagimod Alpha","moa":"APC","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"131I-omburtamab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Mucobuccal Tablet","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"BetterLife Pharma \/ Not Applicable"},{"orgOrder":0,"company":"PharmaBlock Sciences","sponsor":"Shouyao","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"SY-707","moa":"ALK\/FAK\/IGF1R multi-target kinase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"PharmaBlock Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PharmaBlock Sciences \/ Shouyao","highestDevelopmentStatusID":"9","companyTruncated":"PharmaBlock Sciences \/ Shouyao"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Sun Yat-sen University","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Therapeutics \/ Sun Yat-sen University"},{"orgOrder":0,"company":"HebaBiz Biotech","sponsor":"Johnpro Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Siroquine","moa":"Dual autophagy","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"HebaBiz Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HebaBiz Biotech \/ Johnpro Biotech","highestDevelopmentStatusID":"9","companyTruncated":"HebaBiz Biotech \/ Johnpro Biotech"},{"orgOrder":0,"company":"Merck Group","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bintrafusp Alfa","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck Group \/ GlaxoSmithKline","highestDevelopmentStatusID":"9","companyTruncated":"Merck Group \/ GlaxoSmithKline"},{"orgOrder":0,"company":"Immutep","sponsor":"Eoc Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ EOC Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ EOC Pharma"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Mucobuccal Tablet","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Monopar Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"N-803","moa":"IL-15 receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ImmunityBio \/ National Cancer Institute","highestDevelopmentStatusID":"9","companyTruncated":"ImmunityBio \/ National Cancer Institute"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Not Applicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Omburtamab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Not Applicable"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Not Applicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Evorpacept","moa":"CD47","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"131I-omburtamab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebroventricular","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Evorpacept","moa":"CD47","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diethyl Dihydroxyhomospermine","moa":"Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Vidutolimod","moa":"TLR9","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Checkmate Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Checkmate Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Checkmate Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Not Applicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"131I-Omburtamab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Vidutolimod","moa":"TLR9","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Checkmate Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Checkmate Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Checkmate Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"Eryaspase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Erytech Pharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Catalent","highestDevelopmentStatusID":"9","companyTruncated":"Erytech Pharma \/ Catalent"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"N-803","moa":"IL-15","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ImmunityBio \/ Not Applicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Not Applicable"},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Osimertinib Mesylate","moa":"EGFR \/ HER3","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Baili Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Baili Pharmaceutical \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Baili Pharmaceutical \/ AstraZeneca"},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"Vidutolimod","moa":"TLR9","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Checkmate Pharmaceuticals","amount2":0.25,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Injectable\/Injection","sponsorNew":"Checkmate Pharmaceuticals \/ Regeneron","highestDevelopmentStatusID":"9","companyTruncated":"Checkmate Pharmaceuticals \/ Regeneron"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Omburtamab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gritstone bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dabrafenib Mesylate","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Equecabtagene Autoleucel","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Innovent Biologics","highestDevelopmentStatusID":"9","companyTruncated":"IASO Bio \/ Innovent Biologics"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Equecabtagene Autoleucel","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Innovent Biologics","highestDevelopmentStatusID":"9","companyTruncated":"IASO Bio \/ Innovent Biologics"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Tetravalent HPV Vaccine","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Syros Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Merger","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Tyme Technologies \/ Syros","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Syros"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"AL102","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Vigeo Therapeutics","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"VT1021","moa":"CD47","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Vigeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vigeo Therapeutics \/ Biohaven","highestDevelopmentStatusID":"9","companyTruncated":"Vigeo Therapeutics \/ Biohaven"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gritstone bio \/ Hercules Capital","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ Hercules Capital"},{"orgOrder":0,"company":"Amphera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"MesoPher","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Amphera","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amphera \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amphera \/ Not Applicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diethyl Dihydroxyhomospermine","moa":"Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diethyl Dihydroxyhomospermine","moa":"Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Alpha Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zorifertinib","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Alpha Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alpha Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Alpha Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Erythrocytes Encapsulating L-asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Erytech Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"AL102","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"131I-Omburtamab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"AL102","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Syros Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Private Placement","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0.13,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Capsule","sponsorNew":"Tyme Technologies \/ Syros","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Syros"},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Regorafenib","moa":"Tyrosine kinase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Global Coalition for Adaptive Research","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Coalition for Adaptive Research \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Coalition for Adaptive Research \/ Not Applicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Ivospemin","moa":"Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"AL102","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"131I-omburtamab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Merger","leadProduct":"AL102","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ayala Pharmaceuticals \/ Advaxis Immunotherapies","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Advaxis Immunotherapies"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Private Placement","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"Gritstone bio \/ Redmile Group","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ Redmile Group"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Oxford Finance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Evorpacept","moa":"CD47","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"ALX Oncology \/ Oxford Finance","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncology \/ Oxford Finance"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"131I-omburtamab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"AL102","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"AL102","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ivospemin","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"131I-omburtamab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Amphera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Autologous DCs Loaded With PheraLys","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Amphera","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amphera \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amphera \/ Not Applicable"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gritstone bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ Not Applicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ivospemin","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CTX-009","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Compass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"131I-omburtamab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Luveltamab Tazevibulin","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Merger","leadProduct":"AL102","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Advaxis Immunotherapies","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Advaxis Immunotherapies"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"CTX-009","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Compass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ivospemin","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Ivospemin","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"OT-101","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncotelic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Oncotelic Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Alpha Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Zorifertinib","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Alpha Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alpha Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Alpha Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Ivospemin","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"AL102","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ivospemin","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Not Applicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Eftilagimod Alpha","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Roginolisib","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ionctura \/ Not Applicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Not Applicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"Darovasertib","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ideaya Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"9","companyTruncated":"Ideaya Biosciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Geron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Imetelstat","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Geron \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Geron \/ Not Applicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Ivospemin","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Diethyl Dihydroxyhomospermine","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Evorpacept","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Eli Lilly","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncology \/ Eli Lilly"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"AL102","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"Race Oncology Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Bisantrene","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"City of Hope \/ Race Oncology Limited","highestDevelopmentStatusID":"9","companyTruncated":"City of Hope \/ Race Oncology Limited"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ivospemin","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vigeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"VT1021","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Vigeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vigeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Vigeo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ivospemin","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Flucytosine","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Denovo Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Denovo Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Biosight","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Merger","leadProduct":"AL102","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biosight \/ Ayala Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Biosight \/ Ayala Pharmaceuticals"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Not Applicable"},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"Polaris Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Pegargiminase","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Global Coalition for Adaptive Research","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Global Coalition for Adaptive Research \/ Polaris Group","highestDevelopmentStatusID":"9","companyTruncated":"Global Coalition for Adaptive Research \/ Polaris Group"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Odronextamab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sapu Bioscience","sponsor":"Cromos Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Trabedersen","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sapu Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sapu Bioscience \/ Cromos Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Sapu Bioscience \/ Cromos Pharma"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Odronextamab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Evorpacept","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncology \/ Not Applicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Evorpacept","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Piper Sandler","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncology \/ Piper Sandler"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Evorpacept","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Piper Sandler","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncology \/ Piper Sandler"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Evorpacept","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Piper Sandler","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncology \/ Piper Sandler"},{"orgOrder":0,"company":"Biosight","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Merger","leadProduct":"AL102","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Biosight \/ Ayala Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Biosight \/ Ayala Pharmaceuticals"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Darovasertib","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ideaya Biosciences","amount2":0.13,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Ideaya Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"9","companyTruncated":"Ideaya Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"AL102","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"FibroGen \/ Not Applicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ivospemin","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Ivospemin","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Ivospemin","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Immunome","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"AL102","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Ayala Pharmaceuticals \/ Immunome","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Immunome"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Ivospemin","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"AL102","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ayala Pharmaceuticals \/ Bristol Myers Squibb","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Immunome","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"AL102","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Immunome","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Immunome"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Polaris Group \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Polaris Group \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Raludotatug Deruxtecan","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Daiichi Sankyo \/ Not Applicable"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Fluorouracil","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oncotelic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Oncotelic Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Not Applicable"},{"orgOrder":0,"company":"Laminar Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"2-Hydroxyoleic Acid (2-Ohoa); Idroxioleic Acid, Sodium","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Laminar Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Laminar Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Laminar Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"Bevacizumab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Gritstone bio \/ TD Cowen","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ TD Cowen"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ivospemin","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Raludotatug Deruxtecan","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Merck & Co","highestDevelopmentStatusID":"9","companyTruncated":"Daiichi Sankyo \/ Merck & Co"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gritstone bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ Not Applicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"CTX-009","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Compass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"5-Fluorocytosine","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Denovo Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Denovo Biopharma \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"9","companyTruncated":"Denovo Biopharma \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Luveltamab Tazevibulin","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2024","type":"Private Placement","leadProduct":"Pembrolizumab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bicycle Therapeutics","amount2":0.56000000000000005,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.56000000000000005,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"9","companyTruncated":"Bicycle Therapeutics \/ Deep Track Capital"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Ac225-PSMA","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Fusion Pharma","amount2":2.3999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":2.3999999999999999,"dosageForm":"Injection","sponsorNew":"Fusion Pharma \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Fusion Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"VGXI","sponsor":"Sutro Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"Luveltamab Tazevibulin","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"VGXI","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VGXI \/ Sutro Biopharma","highestDevelopmentStatusID":"9","companyTruncated":"VGXI \/ Sutro Biopharma"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Afamitresgene Autoleucel","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Adaptimmune Therapeutics \/ Hercules Capital","highestDevelopmentStatusID":"9","companyTruncated":"Adaptimmune Therapeutics \/ Hercules Capital"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"9","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Laminar Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"2-Hydroxyoleic Acid","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Laminar Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Laminar Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Laminar Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ac225-PSMA","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Fusion Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Fusion Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ivospemin","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Syncona Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"Roginolisib","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ionctura","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Ionctura \/ Syncona Limited","highestDevelopmentStatusID":"9","companyTruncated":"Ionctura \/ Syncona Limited"},{"orgOrder":0,"company":"Hutchmed","sponsor":"HengRui","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Surufatinib","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hutchmed \/ Hengrui","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Hengrui"}]

Find Oncology Drugs in Phase II/III Clinical Development

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The collaboration aims to evaluate Exelixis’ TKI XL092 (zanzalintinib) with Merck’s Keytruda (pembrolizumab) for HNSCC, and with Welireg (belzutifan), an oral HIF-2 alpha inhibitor, for RCC.

                          Brand Name : XL092

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 14, 2024

                          Lead Product(s) : Encoberminogene Rezmadenovec,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Merck & Co

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : IMP321 (eftilagimod alpha) a soluble LAG-3 protein and MHC Class II agonist is being evaluated in combination with paclitaxel under evaluation for treatment of metastatic breast carcinoma.

                          Brand Name : IMP321

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 03, 2024

                          Lead Product(s) : Eftilagimod Alpha,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Granite (GRT-C901/GRT-R902) is patient-specific neoantigen cancer vaccine. It is being evaluated for the treatment of front-line metastatic microsatellite stable colorectal cancer.

                          Brand Name : Granite

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          September 30, 2024

                          Lead Product(s) : GRT-C901,GRT-R902,Bevacizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The Company intends to use the net proceeds to support its upcoming clinical trial focusing on relapse/refractory Acute Myeloid Leukemia evaluating OmnImmune, an allogeneic gamma delta T cell product.

                          Brand Name : OmnImmune

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          August 28, 2024

                          Lead Product(s) : Allogeneic Gamma Delta T Cell Therapy,Cyclophosphamide,Fludarabine Phosphate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Undisclosed

                          Deal Type : Public Offering

                          blank

                          05

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : CTX-009 is a bispecific DLL4/VEGF-A antibody, it is being evaluated in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract tumors.

                          Brand Name : CTX-009

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          August 06, 2024

                          Lead Product(s) : CTX-009,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : ALX148 (evorpacept) is a next generation CD47 blocker, which is being investigated in combination with trastuzumab in patients with HER2-positive gastric/gastroesophageal junction (“GEJ”) cancer.

                          Brand Name : ALX148

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 31, 2024

                          Lead Product(s) : Evorpacept,Trastuzumab,Ramucirumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : GDC-0084 (paxalisib) is a PI3K/mTOR inhibitor small molecule drug candidate, which is being evaluated for the treatment of newly diagnosed glioblastoma.

                          Brand Name : GDC-0084

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 10, 2024

                          Lead Product(s) : Paxalisib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The collaboration aims to advance the clinical development of late-stage product EOS-448 (belrestotug) in combination with Dostarlimab for the treatment of PD-L1 high Non-small Cell Lung Cancer.

                          Brand Name : EOS-448

                          Molecule Type : Large molecule

                          Upfront Cash : $625.0 million

                          July 08, 2024

                          Lead Product(s) : Belrestotug,Dostarlimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : GSK

                          Deal Size : $2,075.0 million

                          Deal Type : Collaboration

                          blank

                          09

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : MTIG7192A (tiragolumab) is an antibody, whch selectively binds to TIGIT. It is currently being evaluated for the treatment of unresectable or metastatic non-squamous non-small cell lung cancer.

                          Brand Name : MTIG7192A

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 04, 2024

                          Lead Product(s) : Tiragolumab,Atezolizumab,Pemetrexed

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : F. Hoffmann-La Roche

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : SBP-101 (ivospemin) is a small molecule AMD1/ODC1 inhibitor, being evaluated in combination with gemcitabine & nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma.

                          Brand Name : SBP-101

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 24, 2024

                          Lead Product(s) : Ivospemin,Paclitaxel,Gemcitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank